drugset
drugset / Trial / NCT00289562

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

NCT00289562 ↗

Phase 1/2 Completed 20 enrolled BioCryst Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride

Timeline

Start
2004-09
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject forodesine Small molecule — —

Indications

B-cell acute lymphoblastic leukemia